34

nanotimes

Companies Facts

trial, to include the superbug MRSA (formally known as Methicillin-resistant Staphylococcus aureus), with E.Coli and Pseudomonas to follow in early 2011.

Initial results from UTHSC Houston last spring show the GBS Quick Tests returned reliable results in ap- proximately four hours. With the current standard of 48-72 hours, this is a markedly significant reduction in testing time. Today’s GBS strains are resistant to ampicillin and amoxicillin and by improving standard detection speed, NanoLogix and the physicians at UTHSC Houston hope to dramatically reduce the overuse of antibiotics in pregnant women and contri- bute to the fight against GBS antibiotic resistance. http://www.nanologix.com

http://www.epa.gov/microbes/mceardnewsarchive.html

http://www.uthouston.edu/media/newsreleases/nr2010/ index.htm?id=2434326

European Society of Cardiology, demonstrates the value of using Nanosphere‘s (NASDAQ: NSPH) Ve- risens™ cTnI assay (RUO) to detect very low levels of troponin I in hospitalized patients with heart failure.

A

The research, conducted at the Veterans Affairs (VA) Hospital in San Diego, was part of the „Veterans Af- fairs Effects of Therapy“ study. In addition to the VA, there were investigators from UCSD and the Cleve- land Clinic. The study employing the Verisens™ assay for troponin I involved 144 patients discharged with acute heart failure, who were followed for 90 days.

clinical study released online by the European Journal of Heart Failure, a publication of the

Both the BNP and the Verisens™ cTnI assay were te- sted on blood drawn at admission, discharge, and up to four consecutive days while hospitalized. The new Verisens™ cTnI assay could quantitatively measure troponin I in more than 99% of blood samples. Even at low concentrations, troponin I in the higher quar- tiles identified increased risk of death and re-hos- pitalization for patients. Additionally, patients who had rising levels at any concentration while treated in the hospital, had a higher risk of death. Of further note, these results were statistically significant for the Verisens™ cTnI assay, but not for BNP. Yang Xue, Paul Clopton, William F. Peacock and Alan S. Maisel: Serial changes in high-sensitive troponin I predict outcome in patients with decompensated heart failure, In: Oxford Journals Medicine, European Journal of Heart Failure, Volume 13(2010), Issue1, January 2011, Pages 37-42, DOI:10.1093/eurjhf/hfq210: http://dx.doi.org/10.1093/eurjhf/hfq210

http://www.nanosphere.us N

anostart AG (OTCQX: NASRY) is investing in Microlight Sensors Pte Ltd. The company,

which is headquartered in Singapore, designs, de- velops and assembles fully-integrated optical sensor and scanning systems for specialty applications in the homeland security and commercial spectral instrumentation systems market. Microlight’s unique high-end optical systems are attributed to its proprie- tary sensor designs and in-house professional team of optical designers and engineers, providing Microlight the capabilities to “tailor-make” optical systems with strict quality assurance controls for customers. Micro- light has developed strong active partnerships with institutions and customers worldwide.

11-01 :: December 2010 / January 2011